<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21881">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02141412</url>
  </required_header>
  <id_info>
    <org_study_id>ANES.MA.10</org_study_id>
    <nct_id>NCT02141412</nct_id>
  </id_info>
  <brief_title>Intravenous Dexamedetomidine for the Prevention of Postoperative Shivering in Patients Undergoing General Anesthesia</brief_title>
  <official_title>Intravenous Dexmedetomidine For The Prevention Of Post-Operative Shivering In Patients Undergoing General Anesthesia: A Dose-Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <authority>Lebanon: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a prospective randomized clinical trial involving adult patients undergoing elective
      surgery under general anesthesia, the investigators will enroll 216 patients, and evaluate 3
      doses of prophylactic dexmedetomidine as a means to reduce postoperative shivering and
      quality of emergence from anesthesia versus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing surgery under general anesthesia may experience several complications
      during the postoperative period. Shivering has been reported to occur in up to 65% of
      patients recovering from general anesthesia, and has been shown to cause detrimental effects
      to the patient. Previous studies have shown that dexmedetomidine 1µg/kg at the end of
      surgery significantly reduces the incidence of postoperative shivering and improves quality
      of emergence from anesthesia. However, this beneficial effect of dexmedetomidine is at the
      expense of prolonged time to extubation and awakening. The aim of this study is to find the
      optimal dose of dexmedetomidine that would be beneficial without delaying recovery from
      general anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Postanaesthetic shivering incidence and score</measure>
    <time_frame>change from baseline every 10 minutes up to 1 hour post-operatively</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of emergence from anesthesia</measure>
    <time_frame>Change from baseline every 5 minutes till extubation</time_frame>
    <safety_issue>No</safety_issue>
    <description>The anesthesiologist blinded to the group allocation will assess patients for coughing, hypertension, tachycardia, limb movement during extubation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's Temperature</measure>
    <time_frame>every 10 minutes up to 1 hour post-operatively</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extubation, awakening and orientation</measure>
    <time_frame>1 hour post-operatively</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation scores</measure>
    <time_frame>every 10 minutes up to 1 hour post-operatively</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>every 10 minutes up to 1 hour post-operatively</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea and vomiting</measure>
    <time_frame>every 10 minutes up to 1 hour post-operatively</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Anesthesia Recovery</condition>
  <condition>Anesthesia Emergence</condition>
  <condition>Shivering</condition>
  <condition>Postoperative Recovery</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Group I will receive dexmedetomidine 0.25 µg/kg IV (over 10 min) at closure of sevoflurane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Group II will receive dexmedetomidine 0.5 µg/kg IV (over 10 min) at closure of sevoflurane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Group III will receive dexmedetomidine 1 µg/kg IV (over 10 min) at closure of sevoflurane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in Group IV will receive same volume of normal saline at closure of sevoflurane</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine 0.25 µg/kg IV</intervention_name>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine 0.5 µg/kg IV</intervention_name>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine 1 µg/kg IV</intervention_name>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 year-old

          -  ASA class I, II, and III

          -  patients undergoing elective surgery under general anesthesia with an estimated time
             of 1-3 h

        Exclusion Criteria:

          -  duration of surgery less than 1h or more than 3 h

          -  allergy to dexmedetomidine

          -  vasoactive antidepressant or analgesics

          -  obesity (BMI&gt;30)

          -  fever

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Aouad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Univesity of Beirut Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Aouad, MD</last_name>
    <phone>+961-1-350000</phone>
    <phone_ext>6380</phone_ext>
    <email>mm01@aub.edu.lb</email>
  </overall_contact>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Aouad, MD</last_name>
      <phone>+961-1-350000</phone>
      <phone_ext>6380</phone_ext>
      <email>mm01@aub.edu.lb</email>
    </contact>
    <contact_backup>
      <last_name>Lama Zahreddine, MS</last_name>
      <phone>+961-1-350000</phone>
      <phone_ext>5411 / 5989</phone_ext>
      <email>lz08@aub.edu.lb</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Marie Awad</investigator_full_name>
    <investigator_title>Professor of Clinical Specialty</investigator_title>
  </responsible_party>
  <keyword>optimal dose of dexmedetomidine</keyword>
  <keyword>prevent shivering</keyword>
  <keyword>improve quality of emergence</keyword>
  <keyword>anesthesia</keyword>
  <keyword>without delay</keyword>
  <keyword>recovery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
